In contrast, Eli Lilly has filed additional patents for Orforglipron-related derivatives, such as patents for tablets (WO2023220112A1), capsules (WO2023220109A1), and dosage regimens for treating type 2 diabetes (T2D) and obesity (WO2024129676A1)
Market Report Scope GLP-1 Receptor Agonist Market Report Coverage Uncover macros and micros vetted on 75+ parameters: Get instant access to report GLP-1 Receptor Agonist Industry News In July 2025, PolyPid Ltd
When commercially available, the projected retail price is $1,000 to $1,500 per month before insurance
DOI: 10.1111/dom.15728
How Rewind Anti-Aging of Miami Can Help Choosing between tirzepatide, retatrutide, and other peptide therapies requires more than reading clinical trial summaries
MHRA-licensed options include semaglutide (Wegovy), liraglutide (Saxenda), orlistat, and tirzepatide (Mounjaro)